Peter Libby: Inflammation and Traditional Risk Factors Work Together in Cardiovascular Disease
Peter Libby, Mallinckrodt Professor of Medicine and Cardiovascular Specialist at Harvard Medical School and Brigham and Women’s Hospital, reposted from International Atherosclerosis Society on LinkedIn:
”Informative new vignettes about Inflammation and Cardiovascular Disease. Inflammation and traditional risk factors work together!
The title echoes a paper I did a few years ago: Strandberg TE, Libby P, Kovanen PT. A tale of two therapies lipid-lowering vs. anti-inflammatory therapy: a false dichotomy? Cardiovasc Pharmacol 2021;7(3):238-241. ”
Qutoing International Atherosclerosis Society‘s post:
”It’s Inflammation Monday!
Every Monday, IAS will be highlighting the recordings of the live lectures from the Inflammation Academy, held in Madrid on August 28, 2025.
For the first lecture highlight, hear from Peter Libby, MD, as he speaks on how inflammatory mechanisms link traditional risk factors to adverse cardiovascular events.
Watch to learn more.”
Stay updated with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis